ACAD - Acadia Pharma GAAP EPS of $0.10 beats by $0.05 revenue of $205.83M misses by $2.75M
2024-05-08 16:10:35 ET
More on Acadia Pharma
- Evaluating Acadia's Market Position Following Pimavanserin's Clinical Setback
- Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
- Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
- Acadia Pharma Q1 2024 Earnings Preview
- Mizuho cuts Acadia to neutral, cites lack of upcoming catalysts